Tillkännagivande • May 01
CodeLab Capital AS announced that it expects to receive NOK 18.8 million in funding from Agil Helse AS and other investor. CodeLab Capital AS announced a private placement to issue 4,700,000 common share at an issue price of NOK 4 for the proceeds of NOK 18,800,000 on April 29, 2026. The demand to subscribe for new shares has been received from the Company’s largest shareholders, Agil Helse AS, and new external investors. Investors that have signed the pre-commitment letters will be allocated at least NOK 17,000,000. Any issuance of new shares in the private placement is subject to the approval by the general meeting. Summons to the general meeting is expected to be sent at the latest by May 6,2026. Reported Earnings • Apr 24
Full year 2025 earnings released Full year 2025 results: Revenue: kr10.8m (up kr10.6m from FY 2024). Net loss: kr14.9m (loss narrowed 90% from FY 2024). New Risk • Mar 17
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr38m free cash flow). Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings have declined by 5.1% per year over the past 5 years. Shareholders have been substantially diluted in the past year (111% increase in shares outstanding). Revenue is less than US$1m (kr162k revenue, or US$17k). Market cap is less than US$10m (€3.64m market cap, or US$4.19m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Tillkännagivande • Dec 30
CodeLab Capital AS, Annual General Meeting, Jun 23, 2026 CodeLab Capital AS, Annual General Meeting, Jun 23, 2026. Board Change • Nov 19
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. CEO & Chairman of the Board Anton Bondesen was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • May 28
CodeLab Capital AS announced that it has received funding CodeLab Capital AS announced a private placement transaction and it has issued 4799998 new shares on May 26, 2025. Tillkännagivande • May 06
CodeLab Capital AS (OB:CODE) signed an agreement to acquire 97.40% stake in Kuba Norge As for NOK 18.5 million. CodeLab Capital AS (OB:CODE) signed an agreement to acquire 97.40% stake in Kuba Norge As for NOK 18.5 million on May 5, 2025. The purchase price is NOK 20 million, to be paid as follows: one third of the purchase price shall be paid in cash at closing of the Transaction, one third of the purchase price shall be paid in kind through the issuance of 1,302,071 consideration shares in CodeLab at Closing, valued at NOK 5.12 per share, one third of the purchase price shall be deferred payment which falls due first quarter of 2028. The deferred payment is subject to adjustment depending on the development of the cash EBITDA of Kuba for 2027, but is capped at 1.5x the original deferred payment.
Following the acquisition of Kuba Norge AS, CodeLab Capital AS is adjusting its leadership structure to align with its strategic direction. CEO Kristian Ikast will transition to the role of Chairman of the Board of Directors and continue as a close advisor to the company. CFO Christoffer Mathiesen will remain in his current role. Anton Lorenz Bondesen, the current Chairman of the Board, will become the CEO and will also continue as a member of the Board of Directors.
The Transaction is subject to standard closing conditions, including the approval of the Company's shareholders in a general meeting for issuance of the Consideration Shares as well as certain other amendments to the share capital of the Company as described below. CodeLab Capital AS has secured approximately NOK 13.9 million in new equity funding for its acquisition of Kuba Norge AS, with contributions from leading shareholders such as Lorenz AS and Codee Holding AS, as well as other existing shareholders and external investors, including the sellers. The funding is at a subscription price of NOK 3.00 per share. CodeLab plans to conduct a private placement to complete the transaction, with a potential subsequent repair issue for minority shareholders.
For the period ending December 31, 2024, Kuba Norge As reported total revenue of NOK 12.5 million.
Advokatfirmaet Schjødt As acted as legal advisor to CodeLab Capital AS. Tillkännagivande • Jan 24
CodeLab Capital AS to Report Fiscal Year 2024 Results on May 15, 2025 CodeLab Capital AS announced that they will report fiscal year 2024 results at 9:00 AM, Central European Standard Time on May 15, 2025 Tillkännagivande • Jan 02
CodeLab Capital AS, Annual General Meeting, Jun 27, 2025 CodeLab Capital AS, Annual General Meeting, Jun 27, 2025. Tillkännagivande • Jul 24
Uniscale, Wholly-Owned Subsidiary of CodeLab Capital, Announces Peter Tuborgh Arnth Nielsen as New Head of Enterprise and Partnerships Uniscale, a wholly-owned subsidiary of CodeLab Capital, announced Peter Tuborgh Arnth Nielsen as the new Head of Enterprise and Partnerships, effective immediately. His role will be crucial in ensuring the growth and development of these strategically important areas of the business. Peter brings extensive experience in building long-term partnerships with international enterprises and large customers. New Risk • Mar 17
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr150m free cash flow). Shares are highly illiquid. Earnings have declined by 49% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€18.4m market cap, or US$20.0m). Board Change • Mar 13
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Tillkännagivande • Oct 28
CodeLab Capital AS to Report Q4, 2023 Results on Feb 23, 2024 CodeLab Capital AS announced that they will report Q4, 2023 results on Feb 23, 2024 Tillkännagivande • May 19
Jesper Melin Ganc-Petersen acquired an unknown minority stake in PatientSky Group AS. Jesper Melin Ganc-Petersen acquired an unknown minority stake in PatientSky Group AS on May 17, 2023.Jesper Melin Ganc-Petersen completed the acquisition of an unknown minority stake in PatientSky Group AS on May 17, 2023. Buying Opportunity • May 03
Now 81% undervalued after recent price drop Over the last 90 days, the stock is down 65%. The fair value is estimated to be €0.20, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to decline by 0.7% per annum. Earnings is forecast to grow by 36% per annum over the same time period. Reported Earnings • Mar 06
Full year 2022 earnings released Full year 2022 results: Revenue: kr194.5m (down 6.8% from FY 2021). Net loss: kr121.3m (loss widened 32% from FY 2021). Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Healthcare Services industry in Europe. Reported Earnings • Nov 16
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: kr46.3m (down 10.0% from 3Q 2021). Net loss: kr29.3m (loss widened 69% from 3Q 2021). Revenue is forecast to stay flat during the next 3 years compared to a 9.9% growth forecast for the Healthcare Services industry in Europe. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Investment Director & Director Sven Bakken was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 13
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: kr46.3m (down 11% from 3Q 2021). Net loss: kr29.3m (loss widened 5.1% from 3Q 2021). Revenue is forecast to stay flat during the next 3 years compared to a 9.8% growth forecast for the Healthcare Services industry in Europe. Reported Earnings • Aug 29
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: kr48.0m (down 6.7% from 2Q 2021). Net loss: kr22.9m (loss widened 26% from 2Q 2021). Over the next year, revenue is expected to shrink by 3.5% compared to a 16% growth forecast for the Healthcare Services industry in Germany. Buying Opportunity • Jul 01
Now 26% undervalued after recent price drop Over the last 90 days, the stock is down 17%. The fair value is estimated to be €0.33, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last year. Earnings per share has declined by 291%. For the next 3 years, revenue is forecast to decline by 2.4% per annum. Earnings is forecast to grow by 24% per annum over the same time period. Reported Earnings • May 21
First quarter 2022 earnings released First quarter 2022 results: Revenue: kr50.1m (down 2.9% from 1Q 2021). Net loss: kr28.0m (loss widened 29% from 1Q 2021). Over the next year, revenue is forecast to grow 18%, compared to a 23% growth forecast for the industry in Germany. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Sven Bakken was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Apr 09
PatientSky Group AS, Annual General Meeting, Jun 28, 2022 PatientSky Group AS, Annual General Meeting, Jun 28, 2022. Reported Earnings • Feb 24
Full year 2021 earnings: Revenues exceed analyst expectations Full year 2021 results: Revenue: kr210.0m (up 50% from FY 2020). Net loss: kr79.4m (loss widened 239% from FY 2020). Revenue exceeded analyst estimates by 3.4%. Over the next year, revenue is forecast to grow 14%, compared to a 42% growth forecast for the industry in Germany. Tillkännagivande • Feb 17
PatientSky Group AS to Report Q4, 2021 Results on Feb 22, 2022 PatientSky Group AS announced that they will report Q4, 2021 results on Feb 22, 2022 Recent Insider Transactions • Sep 04
Chief Commercial Officer recently bought €56k worth of stock On the 1st of September, Egil Noen bought around 150k shares on-market at roughly €0.37 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold €48k more in shares than they bought in the last 12 months. Is New 90 Day High Low • Feb 19
New 90-day low: €1.08 The company is down 17% from its price of €1.29 on 20 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is up 5.0% over the same period. Recent Insider Transactions • Jan 30
Co-founder & CTO recently sold €104k worth of stock On the 27th of January, Andreas Kruger sold around 80k shares on-market at roughly €1.29 per share. This was the largest sale by an insider in the last 3 months. This was Andreas' only on-market trade for the last 12 months. Tillkännagivande • Dec 04
PatientSky Group AS (OB:PSKY-ME) completed the acquisition of Infodoc AS and Acino AS. PatientSky Group AS (OB:PSKY-ME) entered into a conditional share purchase agreement to acquire Infodoc AS and Acino AS for an enterprise value of approx. NOK 280 million on November 9, 2020. The acquisition is of all the shares in Infodoc AS and Acino AS (collectively, Infodec) . The agreed enterprise value of Infodoc in the transaction is approx. NOK 280 million, on a cash-free and debt-free basis and assuming a normalised level of working capital. The purchase price under the transaction is, subject to customary adjustments, expected to be settled in cash upon closing. The completion of the acquisition is subject to customary closing conditions, including, without limitation, that the buyer shall have completed a due diligence review of Infodoc with a satisfactory result to the buyer (in its sole discretion), no material adverse change having occurred, required third party approvals being obtained as well as certain other conditions. The transaction is expected to close during Q4 2020. Advokatfirmaet Thommessen is acting as legal advisor to PatientSky. HLT Advokatfirma AS acted as legal advisor to Infodoc AS.
PatientSky Group AS (OB:PSKY-ME) completed the acquisition of Infodoc AS and Acino AS on December 3, 2020. Tillkännagivande • Nov 11
PatientSky Group AS (OB:PSKY-ME) entered into a conditional share purchase agreement to acquire Infodoc AS and Acino AS for an enterprise value of approx. NOK 280 million. PatientSky Group AS (OB:PSKY-ME) entered into a conditional share purchase agreement to acquire Infodoc AS and Acino AS for an enterprise value of approx. NOK 280 million on November 10, 2020. The acquisition is of all the shares in Infodoc AS and Acino AS (collectively, Infodec) . The agreed enterprise value of Infodoc in the transaction is approx. NOK 280 million, on a cash-free and debt-free basis and assuming a normalised level of working capital. The purchase price under the transaction is, subject to customary adjustments, expected to be settled in cash upon closing. The completion of the acquisition is subject to customary closing conditions, including, without limitation, that the buyer shall have completed a due diligence review of Infodoc with a satisfactory result to the buyer (in its sole discretion), no material adverse change having occurred, required third party approvals being obtained as well as certain other conditions. The transaction is expected to close during Q4 2020. Advokatfirmaet Thommessen is acting as legal advisor to PatientSky. 
